XML 66 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenues (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
PerformanceObligation
Component
Revenues [Abstract]        
Revenue $ 705,138 $ 787,647 $ 587,367  
Commercial Revenue [Member]        
Revenues [Abstract]        
Revenue 293,076 308,591 303,358  
SPINRAZA Royalties [Member]        
Revenues [Abstract]        
Revenue 216,090 240,379 242,314  
WAINUA Royalties [Member]        
Revenues [Abstract]        
Revenue 20,207 0 0  
Other Commercial Revenue [Member]        
Revenues [Abstract]        
Revenue 56,779 68,212 61,044  
TEGSEDI and WAYLIVRA Revenue, Net [Member]        
Revenues [Abstract]        
Revenue 34,189 34,913 30,051  
Other Revenue [Member]        
Revenues [Abstract]        
Revenue 22,590 33,299 30,993  
Research and Development Revenue [Member]        
Revenues [Abstract]        
Revenue 412,062 479,056 284,009  
Collaborative Agreement Revenue [Member]        
Revenues [Abstract]        
Revenue 332,647 352,657 207,222  
WAINUA Joint Development Revenue [Member]        
Revenues [Abstract]        
Revenue 79,415 126,399 $ 76,787  
2013 Strategic Neurology Collaboration with Biogen [Member] | QALSODY [Member]        
Revenues [Abstract]        
Revenue $ 10,000      
WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]        
Revenues [Abstract]        
Revenue   $ 20,000    
Upfront payment received       $ 200,000
Number of material components | Component       4
Number of separate performance obligations | PerformanceObligation       1
Transaction price       $ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca 55.00%